Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 9/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzyl Alcohol SCHEMBL7534814 | 0.92 | MAOB (0.54) | MAOBMEN1KMT2AALOX5FFAR1 | |
| SCHEMBL31160636 | 0.87 | MEN1 (0.59) | MAOBMEN1KMT2AALOX5FFAR1 | |
| SCHEMBL5042093 | 0.87 | ALOX5 (0.55) | MAOBMEN1KMT2AALOX5FFAR1 | |
| SCHEMBL10046165 | 0.87 | MAOB (0.72) | MAOBMEN1KMT2AALOX5LMNA | |
| SCHEMBL308991 | 0.87 | MAOB (0.72) | MAOBMEN1KMT2AALOX5LMNA | |
| SCHEMBL9000924 | 0.84 | MAOB (0.51) | MAOBALOX5CYP1A2RAB9A | |
| SCHEMBL7240384 | 0.82 | MAOB (0.53) | MAOBFFAR1RAB9ASMN1; SMN2 | |
| SCHEMBL28410872 | 0.82 | NR4A2 (0.64) | MEN1KMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL31183087 | 0.81 | CYP1A2 (0.58) | MAOBMEN1KMT2AALOX5FFAR1 | |
| SCHEMBL16886123 | 0.81 | CYP1A2 (0.58) | MAOBMEN1KMT2AALOX5FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025014200-A1 | COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 주식회사 티움바이오 | 2025-01-16 | — | — | WO | disclosed |
| US-11986471-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| US-20230263893-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | ARVINAS OPERATIONS, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230263893-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | ARVINAS OPERATIONS, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230060499-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| EP-3988540-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE (FAAH) ENZYME WITH IMPROVED ORAL BIOAVAILABILITY AND THEIR USE AS MEDICAMENTS | The Regents of the University of California (US) | 2022-04-27 | — | — | EP | disclosed |
| EP-3971191-A1 | BORON-CONTAINING SMALL MOLECULES | Bill And Melinda Gates Foundation (US) | 2022-03-23 | — | — | EP | disclosed |
| EP-3129354-B1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE (FAAH) ENZYME WITH IMPROVED ORAL BIOAVAILABILITY AND THEIR USE AS MEDICAMENTS | UNIV CALIFORNIA (US) | 2022-01-05 | — | — | EP | disclosed |
| CN-113563368-A | Boron-containing small molecules | 比尔及梅琳达盖茨基金会 | 2021-10-29 | — | — | CN | disclosed |
| CN-113321672-A | Boron-containing small molecules | 比尔及梅琳达盖茨基金会 | 2021-08-31 | — | — | CN | disclosed |
| CN-1046903-A | Process for preparing heterocyclic ether derivatives | ICI PLC (GB) | 1990-11-14 | — | — | CN | disclosed |
| EP-0385679-A2 | Heterocyclic cyclic ethers with inhibitory activity on 5-lipoxygenase | ZENECA LIMITED (GB) | 1990-09-05 | — | — | EP | disclosed |
| EP-0385662-A2 | Heterocycles with inhibitory activity of 5-lipoxygenase | ZENECA LIMITED (GB) | 1990-09-05 | — | — | EP | disclosed |
| EP-0385663-A2 | Heterocyclic cycloalkanes as inhibitors of 5-lipoxygenase | ZENECA LIMITED (GB) | 1990-09-05 | — | — | EP | disclosed |
| EP-0385680-A2 | Heterocyclic ethers as 5-lipoxygenase inhibitors | ZENECA LIMITED (GB) | 1990-09-05 | — | — | EP | disclosed |
| EP-0381375-A1 | Heterocyclic derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-08-08 | — | — | EP | disclosed |
| EP-0375368-A2 | Alcohol and ether derivatives | ZENECA LIMITED (GB) | 1990-06-27 | — | — | EP | disclosed |
| EP-0375457-A2 | Cyclic ether derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-06-27 | — | — | EP | disclosed |
| EP-0375452-A2 | Cycloalkane derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-06-27 | — | — | EP | disclosed |
| EP-0375404-A2 | Heterocyclic derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11986471-B2 | Compounds and methods of use | XDH, F12, LPXN | MAOB 290/4885MEN1 182/4885KMT2A 3722/4885 |
| US-20230263893-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | BRPF3, STUB1, BRDT | MAOB 2860/4885MEN1 2783/4885KMT2A 755/4885 |
| US-20230060499-A1 | COMPOUNDS AND METHODS OF USE | XDH, F12, LPXN | MAOB 290/4885MEN1 182/4885KMT2A 3722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.